Oral Semaglutide 14 mg Underwent Phase 3 Evaluation for Early Alzheimer's Disease in evoke(+) Trials
Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer's disease.
Study Design
Population
Patients with early-stage symptomatic Alzheimer's disease.
Intervention
Oral semaglutide 14 mg.
Comparator
Placebo control.
Outcome
Efficacy and safety in early-stage symptomatic Alzheimer's disease.
Abstract
Two phase 3, randomized, placebo-controlled trials (evoke and evoke+) investigated oral semaglutide 14 mg for efficacy and safety in early-stage symptomatic Alzheimer's disease.